Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Switzerland
  4. Swiss Exchange
  5. Basilea Pharmaceutica AG
  6. News
  7. Summary
    BSLN   CH0011432447

BASILEA PHARMACEUTICA AG

(BSLN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Basilea presents preclinical data on synergy between derazantinib and paclitaxel in gastric tumor models at ANE Conference

10/11/2021 | 01:15am EST

(MORE TO FOLLOW) Dow Jones Newswires

October 11, 2021 01:15 ET (05:15 GMT)

All news about BASILEA PHARMACEUTICA AG
11/16Basilea Seeks US FDA's Investigational New Drug Approval For Cancer Therapy
MT
11/16BASILEA PHARMACEUTICA : Updated November 16, 2021
PU
11/16Basilea announces submission of Investigational New Drug application for novel oncology..
DJ
11/16Basilea Pharmaceutica Ltd Announces Submission of Investigational New Drug Application ..
CI
10/11BASILEA PHARMACEUTICA : Therapy Shows Synergistic Anti-Tumor Effects In Gastric Cancer Mod..
MT
10/11Basilea presents preclinical data on synergy between derazantinib and paclitaxel in gas..
DJ
10/11Basilea Pharmaceutica Ltd Presents Preclinical Data on Synergy Between Derazantinib and..
CI
09/30BASILEA PHARMACEUTICA : Asahi Kasei Seek Japanese Nod For Anti-Fungal Drug
MT
09/30Basilea's partner Asahi Kasei Pharma filed New Drug Application for the marketing autho..
DJ
09/30BASILEA PHARMACEUTICA : partner Asahi Kasei Pharma filed New Drug Application for the mark..
AQ
More news
Analyst Recommendations on BASILEA PHARMACEUTICA AG
More recommendations
Financials
Sales 2021 138 M 149 M 149 M
Net income 2021 -22,2 M -24,1 M -24,1 M
Net cash 2021 0,85 M 0,93 M 0,93 M
P/E ratio 2021 -18,8x
Yield 2021 -
Capitalization 442 M 478 M 479 M
EV / Sales 2021 3,21x
EV / Sales 2022 2,58x
Nbr of Employees 160
Free-Float 88,5%
Chart BASILEA PHARMACEUTICA AG
Duration : Period :
Basilea Pharmaceutica AG Technical Analysis Chart | BSLN | CH0011432447 | MarketScreener
Technical analysis trends BASILEA PHARMACEUTICA AG
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 3
Last Close Price 37,38 CHF
Average target price 87,60 CHF
Spread / Average Target 134%
EPS Revisions
Managers and Directors
David Veitch Chief Executive Officer
Adesh Kaul Chief Financial Officer
Domenico Scala Chairman
Laurenz Kellenberger Chief Scientific Officer
Marc Engelhardt Chief Medical Officer
Sector and Competitors
1st jan.Capi. (M$)
BASILEA PHARMACEUTICA AG-27.60%493
MODERNA, INC.215.53%133 648
LONZA GROUP AG29.85%59 443
IQVIA HOLDINGS INC.46.26%50 064
SEAGEN INC.-3.22%30 994
CELLTRION, INC.-40.81%24 431